Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20344302 | 0.84 | POLB (0.51) | POLBCACNA2D1CACNA1BCACNB1LTA4H | |
| SCHEMBL20832991 | 0.80 | CYP2D6 (0.56) | POLBCACNA2D1CACNA1BCACNB1CYP2D6 | |
| SCHEMBL8507267 | 0.80 | CYP2D6 (0.56) | POLBCACNA2D1CACNA1BCACNB1CYP2D6 | |
| SCHEMBL22259900 | 0.80 | CYP2D6 (0.56) | POLBCACNA2D1CACNA1BCACNB1CYP2D6 | |
| SCHEMBL11447515 | 0.80 | POLB (0.47) | POLBCACNA2D1CACNA1BCACNB1LTA4H | |
| SCHEMBL20833013 | 0.80 | CYP2D6 (0.56) | POLBCACNA2D1CACNA1BCACNB1CYP2D6 | |
| SCHEMBL8493732 | 0.79 | POLB (0.59) | POLBCACNA2D1CACNA1BCACNB1LTA4H | |
| SCHEMBL6535642 | 0.78 | CHRNB4 (0.49) | POLBLTA4HCHRNB4CHRNA3SLC6A2 | |
| SCHEMBL10679403 | 0.75 | CYP2D6 (0.62) | POLBCACNA2D1CACNA1BCACNB1CYP2D6 | |
| SCHEMBL10681797 | 0.75 | POLB (0.54) | POLBCACNA2D1CACNA1BCACNB1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | POLB 210/4885CACNA2D1 3083/4885CACNA1B 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.